Pharma & Biotech
Acasti Pharma eyeing FDA meeting as it continues to advance heart disease candidate CaPre
Acasti Pharma edging closer to commercializing CaPre as it eyes topline clinical data for Christmas
Acasti Pharma has global ambitions for its CaPre Omega-3 therapeutic
Only registered members can use this feature.
Copyright © Proactive Investors 2019.
All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC.